Maharashtra allocated 50% of daily Remdesivir requirement: Rajesh Tope

Maharashtra Health Minister Rajesh Tope on Thursday said the state is being allocated 26,000 Remdesivir injections by the Centre as against the requirement of 50,000 vials

Rajesh Tope
Press Trust of India Mumbai
2 min read Last Updated : Apr 22 2021 | 1:00 PM IST

Maharashtra Health Minister

Rajesh Tope on Thursday said the state is being allocated 26,000 Remdesivir injections per day by the Centre as against the requirement of 50,000 vials of the anti-COVID-19 drug.

Talking to reporters here, Tope said he will write to the Centre to increase the allocation of Remdesivir to Maharashtra, the worst COVID-19-hit state in the country.

"The state government's daily requirement is 50,000 Remdesivir injections, but the Centre's allocation is 26,000 injections per day. This is for the next 10 days, which is very serious as timely use of the injections to treat co- morbid and serious COVID-19 patients can save lives," he said.

Remdesivir is listed for use in serious COVID-19 patients. In view of a sudden spike in demand of the drug due to the surge in COVID-19 cases, the Centre last week banned its export till the situation improves.

"I will send a letter to the Union Health Ministry on Thursday to increase the allocation of the key anti-viral drug to Maharashtra," the minister said.

Tope and state Food and Drug Administration minister Rajendra Shingane few days ago had assured that the supply of Remdesivir will increase from April 21.

On Wednesday, the state reported 67,468 fresh coronavirus cases, taking its tally beyond the 40-lakh mark, while 568 more patients succumbed to the infection, as per the health department.

The Bombay High Court on Wednesday came down heavily on the Maharashtra government for its "extremely callous" behaviour towards the issue of procuring and allocating Remdesivir injections for COVID-19 patients, and said the authorities are shirking their responsibilities.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusMaharashtraCoronavirus Vaccine

First Published: Apr 22 2021 | 12:57 PM IST

Next Story